drugset / Trial / NCT01149993
Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients undergoing living donor renal transplant will be asked to participate to determine whether pre-operative dosing of immunosuppressive medication, and the donor organ receiving an additional dose of antibody induction therapy helps to alleviate potential damage to the transplanted organ post-transplant. A number of lab tests will be done post-transplant to determine how well the kidney is functioning.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thymoglobulin | Protein / enzyme biologic | 1.5 mg/kg | Other |
| Subject | Thymoglobulin | Protein / enzyme biologic | 25 mg | Other |
| Subject | mycophenolic acid | Small molecule | 720 mg | — |
Indications
No indication recorded.